MCKESSON CORPORATION |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 544.3 USD | +0.81% |
|
+3.49% | +17.31% |
Financials (USD)
| Sales 2024 * | 312B | Sales 2025 * | 338B | Capitalization | 70.95B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.03B | Net income 2025 * | 3.52B | EV / Sales 2024 * | 0.23 x |
| Net Debt 2024 * | 1.78B | Net Debt 2025 * | 478M | EV / Sales 2025 * | 0.21 x |
| P/E ratio 2024 * |
24.5
x | P/E ratio 2025 * |
19.5
x | Employees | 48,000 |
| Yield 2024 * |
0.44% | Yield 2025 * |
0.51% | Free-Float | 46.58% |
More Fundamentals
* Assessed data
More news
Latest transcript on McKesson Corporation
More recommendations
More press releases
| 1 day | +0.84% | ||
| 1 week | +4.07% | ||
| Current month | +0.58% | ||
| 1 month | +1.39% | ||
| 3 months | +11.02% | ||
| 6 months | +19.19% | ||
| Current year | +16.62% |
1 week
517.82
542.30
1 month
514.88543.00
Current year
462.70543.00
1 year
352.34543.00
3 years
180.42543.00
5 years
112.60543.00
10 years
106.11543.00
| Managers | Title | Age | Since |
|---|---|---|---|
Brian Tyler
CEO | Chief Executive Officer | 57 | 11-12-31 |
| Director of Finance/CFO | 55 | 18-01-26 | |
Francisco Fraga
CTO | Chief Tech/Sci/R&D Officer | 51 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Donald Knauss
CHM | Chairman | 73 | 14-10-19 |
Webster Dunbar
BRD | Director/Board Member | 62 | 22-03-31 |
| Director/Board Member | 66 | 22-01-12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.31% | 1,026 M€ | +6.15% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 543.2 | +0.60% | 334 185 |
| 24-04-25 | 539.9 | +0.84% | 635,557 |
| 24-04-24 | 535.4 | +0.64% | 583,497 |
| 24-04-23 | 532 | +0.89% | 490,789 |
| 24-04-22 | 527.3 | +0.47% | 893,497 |
Delayed Quote Nyse, April 25, 2024 at 04:00 pm EDT
More quotes
McKesson Corporation specializes in pharmaceutical product distribution. The group also offers technological services to healthcare companies. Net sales break down by activity as follows:
- distribution of pharmaceutical products (87%);
- distribution of medical and surgical products (4%);
- other (1.6%): primarily technology services and software sales.
The remaining net sales (7.4%) are from international activities.
Sector
Pharmaceuticals
Calendar
2024-05-07
- Q4 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
539.9
USD
Average target price
559.5
USD
Spread / Average Target
+3.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.62% | 70.95B | |
| +2.99% | 25.25B | |
| +5.13% | 8.67B | |
| +6.46% | 8.16B | |
| -21.01% | 7.91B | |
| -0.61% | 4.51B | |
| +17.12% | 4.31B | |
| -0.14% | 4.07B | |
| -3.30% | 3.84B | |
| +21.70% | 3.63B |
- Stock Market
- Equities
- MCK Stock
